Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756578 | 0.76 | LMNA (0.32) | LMNAMAPTXBP1ATMSMN1; SMN2 | |
| SCHEMBL14886371 | 0.76 | TSHR (0.33) | TSHRSLC7A5TP53 | |
| SCHEMBL23231141 | 0.75 | — | — | |
| SCHEMBL109960 | 0.73 | TSHR (0.41) | TSHRLMNASLC7A5TP53 | |
| SCHEMBL12855900 | 0.73 | — | — | |
| SCHEMBL20334668 | 0.73 | — | — | |
| SCHEMBL23313 | 0.73 | — | — | |
| SCHEMBL5020011 | 0.73 | — | — | |
| SCHEMBL18606094 | 0.73 | — | — | |
| SCHEMBL255878 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20150139907-A1 | CALCIUM-BINDING AGENTS INDUCE HAIR GROWTH AND/OR NAIL GROWTH | UNIV CALIFORNIA (US) | 2015-05-21 | — | — | US | disclosed |
| US-8889156-B2 | Calcium-binding agents induce hair growth and/or nail growth | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120115951-A1 | PROTECTIVE ACTION OF SEROFENDIC ACID ON CARDIAC MUSCLE | Eisai R & D Managment Co., Ltd (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20100239503-A1 | CALCIUM-BINDING AGENTS INDUCE HAIR GROWTH AND/OR NAIL GROWTH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-09-23 | — | — | US | disclosed |
| US-7323519-B2 | Process for producing vinyl polymer, vinyl polymer, and curable composition | KANEKA CORPORATION (JP) | 2008-01-29 | — | — | US | disclosed |
| US-7211589-B2 | Atisane compounds and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-01 | — | — | US | disclosed |
| EP-0277473-A2 | Reversible water-soluble polymer compositions, their manufacture and use in homogeneous catalysis | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150139907-A1 | CALCIUM-BINDING AGENTS INDUCE HAIR GROWTH AND/OR NAIL GROWTH | S100B, S100A6, CALCB | TSHR 1604/4885LMNA 4426/4885MAPT 1463/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | TSHR 543/4885LMNA 3267/4885MAPT 3449/4885 |
| US-20120115951-A1 | PROTECTIVE ACTION OF SEROFENDIC ACID ON CARDIAC MUSCLE | TNNC1, TNNT2, TNNI3 | TSHR 3121/4885LMNA 484/4885MAPT 3681/4885 |
| US-20100239503-A1 | CALCIUM-BINDING AGENTS INDUCE HAIR GROWTH AND/OR NAIL GROWTH | S100B, S100A6, CALCB | TSHR 1604/4885LMNA 4426/4885MAPT 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.